Viskase Holdings, Inc. cash flow statement VISK

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, Viskase Holdings, Inc. generated $454,000 of cash from operations, down 95.5% from the same quarter a year earlier. It spent $6.6 million on capital expenditures. Free cash flow was negative, at -$6.1 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Operating
Depreciation and amortization	—	4	4	4	—	—	—	—	—
Operating cash flow	-43 -434.7%	0 -95.5%	-11 -599.3%	-16 -12747.3%	-16 -6958.8%	10 +2404.5%	2 +831.1%	0 -48.6%	0 -50.3%
Investing
Capital expenditures	—	7	8	9	—	—	—	—	—
Investing cash flow	—	-7	-8	-9	—	—	—	—	—
Financing
Debt issued	—	—	0	1	—	—	—	—	—
Short-term debt repaid	—	7	0	11	—	—	—	—	—
Dividends paid	—	—	—	—	0	0	0	1 +0.0%	0
Financing cash flow	33 +123.6%	6 +395.3%	-2 -118.2%	45 +522.5%	-16	-2	10	7 +663.8%	0
Change in cash
Effect of exchange rate	—	-0	-0	-0	—	—	—	—	—
Net change in cash	-8 -449.5%	-0 +86.5%	-21 -755.5%	19 +39495.9%	-6 -2876.5%	-1 -401.5%	3 +1210.8%	0 +104.8%	0 -50.3%
Free cash flow	—	-6	-19	-25	—	—	—	—	—
Per share
Free cash flow per share	—	-0.43	-1.32	-3.19	—	—	—	—	—
Dividend per share	—	0.00	0.00	0.00	—	—	—	—	—
Shareholder returns
Returned to shareholders	—	—	—	—	0	0	0	1	0
Ratios
Free cash flow margin	—	-6.44%	-20.97%	-29.24%	—	—	—	—	—
Capital expenditures to revenue	—	6.92%	8.54%	10.38%	—	—	—	—	—
Cash conversion	-1.69x	—	—	—	-0.36x	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: VISK (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Lombard, IL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 727510
Former names: ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.